Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 75 of 346 for:    sprains and strains

Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03028909
Recruitment Status : Withdrawn (Study is withdrawn due to company decision.)
First Posted : January 23, 2017
Last Update Posted : March 14, 2019
Sponsor:
Information provided by (Responsible Party):
MedImmune LLC

Brief Summary:
The purposes of this study are to determine if MEDI8852 administered with standard of care (oseltamivir) will reduce the time to normalization of respiratory function for adults who are hospitalized with influenza caused by Type A strains and to determine if MEDI8852 has an acceptable safety profile in adults who are hospitalized with influenza caused by Type A strains.

Condition or disease Intervention/treatment Phase
Influenza - Type A Strains Drug: Oseltamivir Drug: MEDI8852 Drug: Placebo Phase 2

Detailed Description:
The MEDI8852 phase 2b study will evaluate the efficacy and safety of a single intravenous (IV) dose of MEDI8852 or placebo administered in conjunction with oseltamivir in adult subjects who are hospitalized with influenza caused by Type A strains. Approximately 450 subjects will be enrolled at study centers in North America, Europe, and other regions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2b, Randomized, Double-blind, Single-dose, Active-controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Influenza Caused by Type A Strains
Estimated Study Start Date : July 24, 2017
Estimated Primary Completion Date : July 26, 2019
Estimated Study Completion Date : July 26, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot
Drug Information available for: Oseltamivir

Arm Intervention/treatment
Experimental: Oseltamivir + low dose MEDI8852
Low Dose of MEDI8852 + Oseltamivir will be studied
Drug: Oseltamivir
Standard of care for influenza caused by Type A strains
Other Name: Tamiflu

Drug: MEDI8852
MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion.

Experimental: Oseltamivir + high dose MEDI8852
High dose of MEDI8852 + Oseltamivir will be studied.
Drug: Oseltamivir
Standard of care for influenza caused by Type A strains
Other Name: Tamiflu

Drug: MEDI8852
MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion.

Active Comparator: Oseltamivir + Placebo
Oseltamivir in conjunction with placebo will be studied.
Drug: Oseltamivir
Standard of care for influenza caused by Type A strains
Other Name: Tamiflu

Drug: Placebo
Salt-water solution containing no active ingredients.




Primary Outcome Measures :
  1. Evaluation of efficacy as defined as time to normalization of respiratory function. [ Time Frame: Through Day 14 ]
    To evaluate the effect of MEDI8852 administered in conjunction with oseltamivir and the effect of oseltamivir alone in reducing time to normalization of respiratory function.

  2. The occurence of Adverse Events [ Time Frame: Through Day 28 ]
    Occurrence of adverse events.

  3. The occurence of Serious Adverse Events [ Time Frame: Through Study Day 60 ]
    Occurrence of serious adverse events.

  4. The occurence of Adverse Events of Special Interest (AESIs) [ Time Frame: Through Day 60 ]
    Occurrence of Adverse Events of Special Interest.


Secondary Outcome Measures :
  1. Assessment of the effect of MEDI8852 in reducing severity of clinical status. [ Time Frame: Through Day 7 ]
    Evaluation of the effect of MEDI8852 in reducing severity of clinical status defined by death, ICU, non-ICU hospitalization, but requiring supplemental oxygen, non-ICU hospitalization and not requiring supplemental oxygen, not hospitalized, but unable to resume normal activities, fully resumed normal activities

  2. Evaluation of time to hospital discharge. [ Time Frame: Through Day 60 ]
    Evaluation of time to hospital discharge.

  3. Quantitation of influenza viral shedding by qRT-PCR. [ Time Frame: Through Day 60 ]
    Evaluation of the effect of MEDI8852 in reducing the duration and quantity of viral shedding measured by qRT-PCR over time.

  4. Evaluation of serum concentrations and PK of MEDI8852. [ Time Frame: Through Day 60 ]
    To evaluate serum concentration of MEDI8852 through Day 60.

  5. Evaluation of serum ADA responses in serum through Day 60. [ Time Frame: Through Day 60 ]
    To evaluate the ADA response through Day 60.

  6. Evaluation of time to ICU discharge. [ Time Frame: Through Day 60 ]
    Evaluation of time to ICU discharge.

  7. Evaluation of the effect of MEDI8852 in reducing time to clinical resolution of individual vital sign abnormalities. [ Time Frame: Through Day 14 ]
    To evaluate time to clinical resolution of vital sign abnormalities.

  8. Evaluation of Change in NEWS from baseline through Day 14. [ Time Frame: Through Day 14 ]
    To evaluate the effect of MEDI8852 in reducing NEWS.

  9. Evaluation of the effect of MEDI8852 in reducing the duration of mechanical ventilation. [ Time Frame: Through Day 60 ]
    To evaluate duration of mechanical ventilation.

  10. Evaluation of the effect of MEDI8852 in reducing the rates of ICU admission from the general ward. [ Time Frame: Through Day 60 ]
    To evaluate the rate of ICU admission from the general ward.

  11. Evaluation to determine the effect of MEDI8852 on all-cause mortality [ Time Frame: Through Day 60 ]
    To evaluate All-cause mortality.

  12. Evaluation of the effect of MEDI8852 on all-cause re-admission rates during the study. [ Time Frame: Through Day 60 ]
    To evaluate the rate of all-cause re-admission during the study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Age 18 years or older at the time of screening. Written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act [HIPAA] in the United States, Data Privacy Directive in Europe) obtained from the subject/legal representative prior to performing any protocol related procedures, including screening evaluations.

Females of childbearing potential who are sexually active with a nonsterilized male partner must have evidence of not being pregnant upon enrollment and have a negative pregnancy test prior to administration of investigational product. Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy), premenarchal, or postmenopausal (defined as 12 months with no menses without an alternative medical cause). Hospitalized ≤ 72 hours prior to receipt of a positive diagnostic test for influenza A; confirmed with positive rapid antigen test (supplied or approved by the sponsor), or confirmed with culture, polymerase chain reaction, or antigen testing at the study site. Onset of influenza symptoms ≤ 144 hours (≤ 6 days) prior to randomization. Receiving supplemental oxygen. Expected to participate in the study through Day 60.

Exclusion Criteria:

  • Any condition that, in the opinion of the investigator, would interfere with evaluation of study drugs or interpretation of subject safety or study results.
  • Concurrent enrollment in another clinical study involving an investigational treatment. -Hospitalized > 72 hours (> 3 days) prior to receipt of a positive diagnostic test for influenza A.
  • Receipt of > 72 hours or > 6 doses of treatment with a neuraminidase (NA) inhibitor. -Receipt of any investigational antiviral medications within 30 days prior to study drug dosing.
  • Previous receipt of an influenza mAb within past 100 days.
  • Pregnant or nursing female.
  • History of allergic disease or reactions likely to be exacerbated by any components of the study drugs (MEDI8852 or oseltamivir).
  • Diagnosis of influenza B infection within 14 days prior to randomization.
  • Employees of the sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals.

Layout table for additonal information
Responsible Party: MedImmune LLC
ClinicalTrials.gov Identifier: NCT03028909     History of Changes
Other Study ID Numbers: D6000C00003
First Posted: January 23, 2017    Key Record Dates
Last Update Posted: March 14, 2019
Last Verified: April 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by MedImmune LLC:
Influenza A
MEDI8852

Additional relevant MeSH terms:
Layout table for MeSH terms
Sprains and Strains
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Wounds and Injuries
Oseltamivir
MEDI8852
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action